The Medical Letter on Drugs and Therapeutics
Auvi-Q Epinephrine Auto-Injector Returns
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Auvi-Q (Kaléo; previously manufactured and marketed by Sanofi), the epinephrine auto-injector approved by the FDA in 2012 for emergency treatment of anaphylaxis and voluntarily withdrawn in 2015 due to potential inaccurate dosage delivery,1 has become available once more. According to Kaléo, improvements in the manufacturing process have addressed the concerns that led to its recall.

THE DEVICE — No changes were made to the device itself, which is about the length and width of a credit card and as thick as a smartphone. It has an automatic needle retraction system and a red safety guard at the needle-end of the device. Removal of the outer case initiates visual signals and an audio recording that provides step-by-step instructions and a 5-second countdown during the injection process. The shelf-life of the epinephrine in the auto-injector is 18 months; ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Auvi-Q Epinephrine Auto-Injector Returns
Article code: 1515a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian